Recent evidence derived from systematic review and meta-analyses of randomized controlled trials showed that BP-DES have similar efficacy and safety profiles compared with DP-DES in terms of ST, target vessel revascularization, MI, and death. [11] [12] [13] However, there is a paucity of data comparing BP-DES and DP-DES in a real-world setting where patients in clinical practice often have more complex lesions and other comorbidities. 14, 15 Given that protocol-driven angiographic follow-up could inflate the incidence of target lesion revascularization;
observational studies may give a more realistic indication of outcomes and complications. We sought to compare the clinical outcomes of BP-DES and second-generation DP-DES in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) in real-world clinical practice.
| METHODS

| Study design and patients
We conducted a retrospective analysis of patients who had un-
dergone PCI with BP-DES or DP-DES from January 2009 through
October 2015 in a tertiary hospital. Patients were eligible for inclusion if they underwent a successful PCI with placement of either single or multiple stents and had completed one-year of clinical follow-up (hospital visit or telephone assessment) after the proce-
dure. Successful PCI was defined as the reduction of a minimum in-stent diameter to <20% with a final Thrombolysis in Myocardial
Infarction flow grade 3 at the end of the procedure. 16 The BP-DES studied were biolimus A9-eluting stents (Biomatrix and Biomatrix Neoflex, Biosensors) and everolimus-eluting stents (Synergy I and Synergy II, Boston Scientific). The DP-DES studied were everolimuseluting stents (Promus Premier, Boston Scientific; Xience Prime and Xience Xpedition, Abbott Vascular) and zotarolimus-eluting stents (Resolute Integrity and Resolute Onyx, Medtronic). Patients with implantation of a mixture of DP-DES and BP-DES in the index PCI procedure were excluded. The index PCI was performed based on standard guidelines. 16 All patients were loaded with aspirin and clopidogrel/ticagrelor/prasugrel prior to the procedure. Patients were prescribed with dual antiplatelet therapy (DAPT) for 1 year after the procedure. Systematic follow-up of all patients was conducted at 30 days and 1 year by clinical visits or telephone calls.
Ethical approval for the study was obtained from institutional review board.
| Study outcomes
The primary outcomes of interest included target lesion failure 
| Statistical analysis
Continuous variables were presented as mean + standard deviation and compared between the treatment groups using the Student t test.
Categorical variables were presented as counts and percentages, and compared between the treatment groups using Pearson chi-square test or Fisher's exact test (for frequency of any cell <5).
Due to the nonrandomized nature of patient recruitment into this study, propensity score matching was conducted based on logistic regression model to account for confounders and minimize the treatment selection bias. 19, 20 Variables previously shown to be The cumulative incidence of clinical outcomes was estimated using Kaplan-Meier analysis in the matched cohort and the between-group difference was compared using a log-rank test.
Univariate and multivariate Cox proportional hazards models were used to determine the hazard ratio (HR) and their 95% confidence interval (CI) for occurrence of events by adjusting for the following characteristics: age, gender, ethnicity, diabetes mellitus, chronic renal failure, premature CAD, indication for PCI, lesion complexity, stent width, stent length, and number of stents. In subgroup analyses of TLF, Cox model was used to assess the HR (95% CI) for events rates within each of the following subgroups: age (≥65), gender, indication for PCI, diabetes mellitus, lesion complexity, intravascular imaging-guided stenting, number of vessels, and number of stents.
We tested for interactions between assigned treatment and each subgroup using the likelihood-ratio test after estimation. For all analyses, a two-sided P value of <.05 was considered statistically significant. All statistical analyses were performed on STATA version 13 (StataCorp. College Station, TX, USA).
| RESULTS
| Characteristics of study population
Of 1065 patients who met the study inclusion criteria, 568 (53.3%)
had BP-DES implantation and 497 (46.7%) had DP-DES implantation.
Majority (97.7%) of the patients received peri-procedural DAPT (71% on aspirin plus clopidogrel, 16.4% on aspirin plus prasugrel, and 10.2%
on aspirin plus ticagrelor). The distribution of antiplatelet agents used was comparable between the two groups. After propensity score matching, there were 497 matched pairs of patients. Details of the patient and procedural characteristics are shown in Table 1 . All variables were well balanced between the two groups with standardized mean difference <0.1 (Table S1 ).
| Clinical outcomes
During the first 30 days of follow-up, the TLF rates were numerically higher in DP-DES compared to BP-DES (6.4% vs 4.2%, P = .12) in the propensity score-matched population, but the difference did not reach statistical significance (Table 2) . Similarly, there was no difference in other clinical outcomes including ST (0.4% vs 0.4%, P = 1.00) between BP-DES and DP-DES.
At one-year follow-up, the rate of TLF did not differ significantly between BP-DES and DP-DES (8.7% vs 9.1%, P = .823) in the propensity score-matched population (Table 2) . Similarly, we did not identify any significant difference in other clinical outcomes including ST (0.8% vs 0.8%, P = 1.00), target vessel failure (8.9% vs 9.5%, P = .741), instent restenosis (1.8% vs 1.0%, P = .282), and cardiac death (6.4% vs 7.4%, P = .533) at 1 year.
| Survival analysis
In the propensity score-matched population, the incidence of TLF was not significantly greater in the BP-DES compared with the DP-DES group (10.1% vs 9.6%, log-rank P = .80) as shown in Kaplan-Meier curves in Figure 1 . Multivariate cox regression analysis showed that the risks of TLF were comparable in BP-DES and DP-DES (HR 0.94, 95% CI: 0.61-1.43) in (Table S2) .
| Subgroup analysis
The subgroup analysis revealed that the risk of TLF was not lower with BP-DES than with DP-DES in each of the prespecified subgroups ( Figure 2 ).
| DISCUSSION
New generation DES (BP-DES or DP-DES) have been extensively evaluated in published studies and demonstrated to be associated with improved efficacy and safety profiles compared to first-generation DES. [6] [7] [8] [9] [10] Recent evidence derived from systematic review and metaanalyses of randomized controlled trials showed that BP-DES have similar efficacy and safety profiles compared with DP-DES.
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However, there is a paucity of clinical data on comparative outcomes between BP-DES and DP-DES in real-world patients undergoing PCI.
Using an all-comers PCI database, our study did not demonstrate bet- 6.5% vs 6.7%), respectively. [25] [26] [27] Notably, our study reported relatively higher overall TLF event rates at 1 year compared with these published trials. 25, 26 We postulate that this difference could be attributed to the different study populations analyzed. In our analysis, we included a relatively larger proportion of patients who received PCI due to AMI compared with to 5%-50% This could be explained by the inflated incidence of revascularization as a result of protocol-driven follow-up angiography in controlled clinical trials. 15 Conversely, in a real-world setting, only symptomatic patients could be identified and referred for revascularization. The safety and efficacy of BP-DES and DP-DES were similar to that reported in a Korean registry, 14 which reported comparable clinical outcomes at one-year and two-year follow-up.
The pathophysiological mechanisms responsible for late or very late ST are complex with the persistence of polymer coatings after completion of the drug release being one of the important factors.
The polymer-induced vessel wall inflammation could result in delayed healing and endothelial dysfunction. 4, 29 Other factors such as stent malapposition, neoatherosclerosis, and uncovered struts also serve as a source for future episodes of ST. 30 Based on the eventual report of the LEADERS trial, 31 the incidence of definite ST of BP-DES started to emerge at 2 years and showed significant difference from 2 to 5 years compared with sirolimus-based DP-DES. In contrast, in the SORT OUT VI study, zotarolimus-based DP-DES and biolimus-based BP-DES were associated with similar clinical outcomes including ST. 32 Therefore, it remains unclear whether the potential benefit of BP-DES in reducing the risk of late or very late ST might become evident during longer-term follow-up.
We performed subgroup analyses to explore the difference in treatment benefits between BP-DES and DP-DES based on important and clinical relevant baseline characteristics including age (>65 years old), presence of diabetes, presence of chronic renal failure, index PCI due to AMI and B2/C ACC/AHA lesion class. Notably, chronic kidney disease has emerged as an important predictor of PCI outcomes regardless of the presence of underlying diabetes mellitus. 33, 34 In this T A B L E 1 (Continued) current study, we did not detect any significant difference in clinical outcomes between BP-DES and DP-DES in subgroups of patients with diabetes or chronic kidney disease. These findings derived from subgroup analysis need to be interpreted with caution due to the relatively small sample size of each subgroup.
Given the paucity of data on real-life clinical benefits between BP-DES and DP-DES, our study provided useful insights on the use of new generation DES in real-world practice where patients may have more severe coronary artery disease and more complex lesions. In the present study, we included a relatively larger proportion of patients who received PCI due to AMI and patients with complex lesions compared to published trials. [25] [26] [27] We also analyzed both composite endpoints, such as target lesion revascularization, and individual endpoints, such as ST and cardiac death, to gain a more in-depth understanding on the safety profile of new generation DES with respect to hard clinical endpoints.
Our study should be interpreted in the context of its limitations.
Although propensity score matching was performed to account for potential confounders in treatment selection, other unmeasured confounding could not be accounted for. In our clinical practice, as DAPT was prescribed for 1 year to patients after PCI implanted with either BP-DES or DP-DES, we were unable to evaluate the impact of differential DAPT duration. Finally, our findings need to be interpreted with caution due to the relatively small sample size of each stent group and the low overall incidence of late ST events may require a larger sample to detect any statistical significant difference in late ST events. F I G U R E 1 Kaplan-Meier survival curve describing the cumulative incidence of target lesion failure and stent thrombosis over 1 y. The cumulative incidence of target lesion failure and stent thrombosis for biodegradable polymer drug-eluting stents (BP-DES) and secondgeneration durable polymer drug-eluting stents (DP-DES) was not statistically significant at 1 y after the index percutaneous coronary intervention (PCI)
| CONCLUSION
The safety and efficacy of BP-DES were not better than DP-DES at one-year follow-up in this retrospective analysis of patients undergoing PCI at a tertiary medical center. It remains to be determined whether the biodegradable polymer design of DES could improve outcomes, particularly the risk of very late ST, in longer-term follow-up studies.
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